ERBB2 and breast carcinoma: HER2/erbB2 expression in breast cancer is one of the best known examples of this paradigm with high levels of expression indicating poor prognosis and at the same time favorable response to antibody therapy with anti-HER2 antibody treatment, e.g., with trastuzumab.